Associated tags: FDA, GRB2, Acute myeloid leukemia, Bone marrow, IND, RNA interference, STAT3, Lymphoma, Holding, Pharmaceutical industry, Patient, AML
Locations: GA, BELLAIRE, TX, US, UNITED STATES
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent corporate developments.
Key Points:
- HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2023 and provided an update on recent corporate developments.
- General and administrative expense for both the three months ended March 31, 2023 and March 31, 2022 was $1.3 million.
- As of March 31, 2023, the Company had cash of $6.7 million, compared to $10.4 million as of December 31, 2022.
- ET to review these first quarter 2023 financial results and to provide a general update on the Company.
ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.
Key Points:
- ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.
- To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time.
- A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com .
- An archived webcast will be available on the Bio-Path website approximately two hours after the event.
Holding,
GRB2,
Clinical trial,
Hope,
Acute myeloid leukemia,
AML,
Patient,
Cancer,
Research,
Safety,
Pharmaceutical industry,
Medical imaging,
Cryptocurrency “We see continued enthusiasm from clinical investigators and patients alike and hope to make even more progress toward completing these key studies.
Key Points:
- “We see continued enthusiasm from clinical investigators and patients alike and hope to make even more progress toward completing these key studies.
- As of December 31, 2022, the Company had cash of $10.4 million, compared to $23.8 million at December 31, 2021.
- Net cash provided by financing activities for the year ended December 31, 2022, was $1.7 million.
- ET to review these full-year 2022 financial results and to provide a general update on the Company.
ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
Key Points:
- ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
- To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time.
- A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com .
- An archived webcast will be available on the Bio-Path website approximately two hours after the event.
Clinical trial,
Pancreatic cancer,
Lymphoma,
CLL,
Survival,
New York Medical College,
Patient,
University,
STAT3,
COVID-19,
FDA,
RNA interference,
Safety,
RNA,
Cancer,
AML,
Holding,
Drug discovery,
IND,
Chronic lymphocytic leukemia,
Fine chemical,
Medical imaging,
Nursing,
Vaccine,
Pharmaceutical industry,
Decitabine HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update.
Key Points:
- HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update.
- Two of the three cohorts in the clinical trial already exceed the minimum efficacy required for enrollment expansion.
- Bio-Path’s clinical development program consists of one Phase 2 clinical trial and three Phase 1 or 1/1b clinical trials.
- Phase 2 Clinical Trial – Bio-Path’s Phase 2 clinical trial is treating Acute Myeloid Leukemia (AML) patients.
Retrieved on:
Wednesday, December 7, 2022
University,
Intellectual property,
Annual report,
Security (finance),
Neoplasm,
Lymphatic system,
Safety,
Lymphoma,
Maintenance,
GRB2,
RNA interference,
STAT3,
Acute myeloid leukemia,
Paclitaxel,
MD Anderson Cancer Center,
IND,
Patent,
Uncertainty,
Holding,
COVID-19,
Patient,
Pharmaceutical industry The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
Key Points:
- The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
- The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.
- This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws.
- Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Retrieved on:
Tuesday, November 15, 2022
COVID-19,
Drug discovery,
Patient,
AML,
IND,
RNA interference,
Holding,
Acute myeloid leukemia,
GRB2,
Annual report,
Maintenance,
Research,
Patent,
Security (finance),
Sale,
STAT3,
Intellectual property,
Lymphoma,
Uncertainty,
FDA,
Lymphatic system,
Pharmaceutical industry HOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments.
Key Points:
- HOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2022 and provided an update on recent corporate developments.
- The third quarter was marked by continued progress across our entire DNAbilize pipeline.
- As of September 30, 2022, the Company had cash of $13.7 million, compared to $23.8 million at December 31, 2021.
- ET to review these third quarter 2022 financial results and to provide a general update on the Company.
Retrieved on:
Tuesday, November 8, 2022
GLOBE,
IND,
Lymphoma,
Holding,
GRB2,
Acute myeloid leukemia,
Technology,
STAT3,
NASDAQ,
RNA interference,
Lymphatic system,
FDA,
Pharmaceutical industry ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.
Key Points:
- ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.
- To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time.
- A live audio webcast of the call will also be available on the Presentations section of the Companys website, www.biopathholdings.com .
- In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.
GRB2,
Exercise,
RNA interference,
LLC,
Maintenance,
Sale,
Patent,
GLOBE,
Lymphoma,
Holding,
FDA,
Intellectual property,
IND,
Uncertainty,
Acute myeloid leukemia,
COVID-19,
Intention,
Securities Act of 1933,
Regulation D,
Annual report,
U.S. Securities and Exchange Commission,
STAT3,
NASDAQ,
Lymphatic system,
Form,
Technology,
Security (finance),
SEC,
Roth Capital Partners,
Pharmaceutical industry Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants.
Key Points:
- Additionally, in a concurrent private placement, Bio-Path has also agreed to issue to such investors unregistered warrants.
- The offerings are expected to close on or about November 9, 2022, subject to the satisfaction of customary closing conditions.
- Roth Capital Partners is acting as the sole placement agent for the offerings.
- A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov .
U.S. Securities and Exchange Commission,
Uncertainty,
RNA transfection,
Medicine,
Hospital,
Acute myeloid leukemia,
IND,
AML,
MD Anderson Cancer Center,
Lymphoma,
Weill Cornell Medicine,
Annual report,
NASDAQ,
GRB2,
Patient,
RNA interference,
Joe Byrd (Cherokee Nation Principal Chief),
Lymphatic system,
Scripps Health,
Security (finance),
STAT3,
Clinical,
Cornell University,
Technology,
University,
Department,
Patent,
Safety,
Intention,
GLOBE,
Clinical trial,
Maintenance,
Intellectual property,
Life expectancy,
Holding,
COVID-19,
BH3,
Cancer,
D.O,
Pharmaceutical industry,
Decitabine We are delighted to have dosed the first patient in this key clinical trial.
Key Points:
- We are delighted to have dosed the first patient in this key clinical trial.
- BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers.
- By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
- The Companys second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia.